Lupus Patients May Benefit From Organ-Transplant Rejection Drug
A compound related to a drug used in humans to prevent organ-transplant rejection attacks a key biochemical process in the faulty immune cells of lupus-prone mice, suggesting a possible new approach to combating the disease, UT Southwestern Medical Center researchers have found.”We found that an analog of rapamycin is very effective in improving all aspects of the disease in lupus-prone mice,” said Dr.
